MeiraGTx Holdings (MGTX) Cash & Current Investments (2017 - 2026)
MeiraGTx Holdings' (MGTX) quarterly Cash & Current Investments came in at $65.9 million in Q4 2025, down 36.4% YoY from $103.7 million in Q4 2024, and up 344.25% on a QoQ basis from $14.8 million in Q3 2025.
Analysis
MeiraGTx Holdings (MGTX) Cash & Current Investments (2017 - 2026) Analysis & Trends
MeiraGTx Holdings (MGTX) has 9 years of Cash & Current Investments data on file, last reported at $65.9 million in Q4 2025.
- Quarterly Cash & Current Investments fell 36.4% year-over-year to $65.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $65.9 million (down 36.4% YoY) and the FY2025 annual result came in at $65.9 million, down 36.4% from the prior year.
- Cash & Current Investments improved to $65.9 million in Q4 2025, from $14.8 million in the prior quarter.
- In the past five years, Cash & Current Investments ranged from a high of $199.4 million in Q1 2021 to a low of $14.8 million in Q3 2025.
- A 5-year average of $102.8 million and a median of $108.7 million in 2022 frame the typical range for Cash & Current Investments.
- Annual changes were most pronounced in 2024 — Cash & Current Investments surged 94.14% — and 2025, when it tumbled 88.13%.
- Tracing MGTX's Cash & Current Investments over 5 years: stood at $137.7 million in 2021, then retreated by 16.11% to $115.5 million in 2022, then increased by 13.1% to $130.6 million in 2023, then slipped by 20.66% to $103.7 million in 2024, then plunged by 36.4% to $65.9 million in 2025.
- The last three Cash & Current Investments figures came in at $65.9 million (Q4 2025), $14.8 million (Q3 2025), and $32.2 million (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 7.99 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 5.18 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.14 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 5.10 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 3.31 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 836.99 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.16 Bn |
| 10 | MeiraGTx Holdings | 1.27 Bn | 1.13 Bn | 315.67 Mn | 143.17 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 143.17 Mn |
| Dec 31, 2025 | 65.93 Mn |
| Sep 30, 2025 | 14.84 Mn |
| Jun 30, 2025 | 32.17 Mn |
| Mar 31, 2025 | 66.52 Mn |
| Dec 31, 2024 | 103.66 Mn |
| Sep 30, 2024 | 125.03 Mn |
| Jun 30, 2024 | 101.03 Mn |
| Mar 31, 2024 | 120.27 Mn |
| Dec 31, 2023 | 130.65 Mn |
| Sep 30, 2023 | 64.40 Mn |
| Jun 30, 2023 | 92.77 Mn |
| Mar 31, 2023 | 68.78 Mn |
| Dec 31, 2022 | 115.52 Mn |
| Sep 30, 2022 | 114.71 Mn |
| Jun 30, 2022 | 72.11 Mn |
| Mar 31, 2022 | 113.78 Mn |
| Dec 31, 2021 | 137.70 Mn |
| Sep 30, 2021 | 143.63 Mn |
| Jun 30, 2021 | 172.56 Mn |